Navigating GLP-1 Side Effects: A Practical Guide for Patients
A comprehensive guide to managing the common gastrointestinal side effects of GLP-1 medications and strategies to preserve lean muscle mass during treatment.
Latest Coverage
Beyond Weight Loss: The Cardiovascular Benefits of GLP-1 Receptor Agonists
Recent studies reveal that GLP-1 receptor agonists offer significant cardiovascular protection independent of weight loss, shifting the paradigm in preventative cardiology.
May 20, 2026 • 5 min readBeyond Weight Loss: The Cardiovascular Paradigm Shift of GLP-1 Receptor Agonists
Exploring the paradigm shift of GLP-1 receptor agonists from weight loss and diabetes management to potent cardiovascular risk reduction based on landmark clinical trials.
May 20, 2026 • 6 min readGastroparesis on GLP-1s: A Quiet Safety Signal Patients Deserve to Hear About
Reports of stomach paralysis linked to semaglutide and tirzepatide are rising. Here is what the published evidence actually shows, who is at higher risk, and what proper monitoring looks like.
May 13, 2026 • 6 min readThe Oral GLP-1 Race: Orforglipron, Rybelsus, and the End of the Needle?
Eli Lilly's orforglipron, Novo's next-gen oral semaglutide, and Pfizer's danuglipron exit represent the most consequential pipeline shift in metabolic medicine. Here is the evidence as it stands in 2026.
May 13, 2026 • 7 min readSemaglutide vs. Tirzepatide: What the Head-to-Head Data Actually Shows
A clinical comparison of semaglutide and tirzepatide based on SURMOUNT-5, STEP, and SURPASS data — efficacy, tolerability, and what the receptor pharmacology tells us about who responds best.
May 13, 2026 • 7 min read